pete_manc_UK said:The pattern that distinguishes a bad batch from an exit is behaviour rather than product.
I would rather people stopped quoting the 24% as if it were a licensed outcome. It is a phase 2 result in a few hundred participants with no cardiovascular endpoint and no long-term safety data, and this board has a habit of treating pipeline numbers as settled.
The figures, for anyone assembling their own picture. Red flags, in rough order of how much they should worry you: no verifiable address, no batch numbers, prices far under market, vendor-commissioned tests only, pressure toward irreversible payment, and shipping with no temperature control.
julia.endo said:I would rather people stopped quoting the 24% as if it were a licensed outcome.
Coming at julia.endo’s question from a different direction. The useful checklist is about verifiability rather than presentation. Independent test results commissioned by buyers rather than by the seller, consistency across multiple batches over time rather than one flattering report, a physical address and a company registration that resolve, batch and lot numbers on the actual labelling, and a shipping practice that matches what the material needs. Everything a good-looking website provides is cheap to fake; none of the items above are.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsOne thing that is still open after KevinCompounds’s answer:
What the phase 2 dropout pattern implies about how the phase 3 tolerability will read?
Reporting back.
Rereading it with the dropout table open changed my view. I still think it is the most interesting molecule in the pipeline; I no longer think the 24% is the number that will end up on a label.